CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
8.28
+0.31 (3.89%)
At close: Aug 13, 2025, 4:00 PM
8.16
-0.12 (-1.39%)
Pre-market: Aug 14, 2025, 9:11 AM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | (650) 407-2376 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 71902K402 |
| ISIN Number | US71902K4022 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
| Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 29, 2025 | EFFECT | Notice of Effectiveness |
| Jul 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 25, 2025 | 424B3 | Prospectus |
| Jul 21, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 14, 2025 | 424B3 | Prospectus |
| Jul 14, 2025 | 8-K | Current Report |
| Jul 8, 2025 | 8-K | Current Report |
| Jul 2, 2025 | 424B3 | Prospectus |